PRINCETON, N.J. and LONDON--(BUSINESS WIRE)--Results from an 18-week phase 3b study in adults with type 2 diabetes with inadequate glycemic control on metformin therapy alone found that the addition of treatment with ONGLYZA™ (saxagliptin) 5 mg per day achieved the primary objective of demonstrating non-inferiority compared to the addition of treatment with JANUVIA® (sitagliptin) 100 mg per day in reducing HbA1c from baseline. In this study, overall adverse events were reported at a similar rate for individuals taking ONGLYZA 5 mg plus metformin and JANUVIA 100 mg plus metformin. This study was submitted to the European Medicines Agency (EMEA) as part of the Marketing Authorization Application for ONGLYZA. Complete findings from this study will be submitted for publication in the first half of 2010.
